Move to topTop
April 20, 2022

- April 20, 2022 - Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the Thoraflex Hybrid Frozen Elephant Trunk (FET) device for commercial sale in the United States for the treatment of patients with complex aortic arch disease.

Thoraflex Hybrid is the first of its kind device used in Frozen Elephant Trunk (FET) repair in the United States and was granted Breakthrough Device Designation by the FDA in 2020.

Thoraflex Hybrid is a single use medical device combining a Gelweave polyester graft with a Nitinol self-expanding stent graft and is indicated for the open surgical repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta in cases of aneurysm and/or dissection.

Joseph Coselli, MD (Professor, Executive Vice Chair, Division of Cardiothoracic Surgery, Baylor College of Medicine, Houston, Texas, US) the Principal Investigator commented: “This approval represents a significant milestone in the treatment of patients who need total aortic arch replacement and have significant disease of the descending thoracic aorta. They can now be treated anytime in a single stage procedure with this hybrid device rather than two procedures which has been the conventional pathway in the United States for this group of patients. This, in turn, has led to lowering the risk of major adverse events by 22.6%, in the first year, over traditional treatments.”

Dr. Coselli continued: “Thoraflex Hybrid facilitates secondary interventions for distal extension and, in the United States, is designated for usage with Terumo Aortic’s RelayPro NBS device. This unique labelling aspect provides surgeons with additional confidence should patients have continued aortic disease progression.”

Paul Kuznik, President of Terumo Aortic North America, added: “The FDA approval of Thoraflex Hybrid is a tremendous opportunity for Terumo Aortic in the United States. This innovative hybrid device complements our open surgical graft and endovascular portfolio making us one of the strongest medical device companies within the aortic space, helping to deliver our commitment to provide solutions for every aorta.”

Thoraflex Hybrid received CE Mark approval in 2012 with more than 13,000 devices sold commercially around the world over the past 10 years. This device is integral to Terumo Aortic’s market-leading portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.

 

About Terumo Aortic
At Terumo Aortic, we partner with our customers to revolutionise aortic care. We deliver innovation, versatility and precision with the broadest range of solutions that can be 
personalised for every patient. We are further complementing our implantable device portfolio through the development of digital technologies.

 

Notes to Editors

  • Terumo acquired Vascutek Ltd. in 2002 and Bolton Medical Inc in 2017
  • Terumo Aortic has over 1,250 employees around the world with manufacturing facilities in Glasgow, Scotland and Sunrise, Florida.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.